This content is machine translated BRCA-mutated advanced ovarian cancer. PARP inhibitor shows long-term benefit in terms of PFS Ovarian cancer is the eighth leading cause of death among women with cancer worldwide. In Switzerland, approximately 620 patients are newly diagnosed with ovarian cancer each year. Approximately 22% of…
View Post 3 min This content is machine translated Non-small cell lung cancer and other solid tumors In the pipeline: KRAS G12C inhibitor Sotorasib The KRAS gene is one of the most frequently mutated oncogenes in human cancers and thus represents a promising target in the therapy of diverse solid tumors. Sotorasib is currently…
View Post 5 min This content is machine translated Non-small cell lung cancer Many lids for many pots In the treatment of non-small cell lung cancer, an extremely large amount has been achieved in a short time. Keeping track of so many rapid innovations can be quite difficult,…
View Post 3 min This content is machine translated Myeloid diseases New trends in the treatment of acute myeloid leukemia Understanding about myeloid diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), is becoming more concrete thanks to intensive research. Recent study results have shown that there is…
View Post 3 min This content is machine translated Blood-brain barrier When breast cancer invades the brain Patients with breast cancer can develop metastases in the brain – which means an even worse chance of survival. There may be factors in the blood that can predict this…
View Post 2 min This content is machine translated Non-small cell lung cancer Focus on current therapy management of NSCLC Non-small cell lung cancer is a common cancer with generally poor prognosis. Scientific advances have led to new forms of therapy increasing the chance of survival. In particular, the development…
View Post 4 min This content is machine translated Immunotherapy A narrow ridge With the rapid development of new, highly efficient anticancer drugs such as checkpoint inhibitors, an expanded spectrum of side effects of oncological therapies inevitably arises. The increasing use of immunotherapy…
View Post 2 min This content is machine translated Hypertrophic cardiomyopathies (HCM) Recognize rare causes This training course is all about differential diagnosis and therapy of hypertrophic cardiomyopathies (HCM). First, the previously known etiologies and their respective frequencies are highlighted. The very large group of…
View Post 2 min This content is machine translated Schwartz-Bartter syndrome Effectively balancing electrolyte imbalances: focus on osmoregulation Nausea, vomiting, headaches and muscle cramps may also result from water retention. In Schwarzt-Bartter syndrome, this is triggered by ADH accumulation. The cause is usually small cell lung cancer, but…
View Post 3 min This content is machine translated Cancer medicine of the future Car-T cell therapy and its application in practice CAR-T cell technology is considered the latest achievement in cancer medicine. The first approvals in Europe took place in mid-2018 – Switzerland followed at the end of 2018. Currently, the…
View Post 2 min This content is machine translated Multiple Myeloma Challenge accepted: Breaking boundaries in therapy Multiple myeloma is rare, but is one of the most common tumors of bone and bone marrow. Annually, there are about six to eight new cases per 100,000 inhabitants. Almost…
